New drugs could prevent migraine attacks from occurring
Washington: Researchers have developed drugs that are aimed at preventing migraine attacks from occurring, rather than stopping the attacks once they have started.
These studies are the first to test monoclonal antibodies for the prevention of migraine, and both are directed against a relatively new target in migraine prevention, the calcitonin gene-related peptide, or CGRP.
Both are phase II studies, meaning larger studies are needed to confirm the results.
One study involved 163 people who had migraine from five to 14 days per month. They received either a placebo or a single IV dose of a drug called ALD403 and then were followed for 24 weeks. Those who received the drug had an average of 5.6 fewer migraine days per month, a 66-percent decrease, compared to 4.6 fewer days per month for those who received a placebo, or a 52-percent decrease. Sixteen percent of those who received the drug had no migraine days at 12 weeks, while none of those who received the placebo were free from migraine at that point.
In the other study, 217 people who had migraine four to 14 days per month received biweekly subcutaneous injections of either a placebo or a drug called LY2951742 for 12 weeks.
Those who received the drug had an average of 4.2 fewer migraine days per month at 12 weeks, or a 63-percent decrease, while those who received placebo had 3 fewer migraine days per month, or a 42-percent decrease.
More from India
More from World
More from Sports
More from Entertaiment
- Sunanda Pushkar murder case: Police may approach court seeking lie detector test on Shashi Tharoor
- Check JEE (Main) 2015 rank on www.jeemain.nic.in, cbseresults.nic.in
- Jawaharlal Nehru's Wikipedia page edited from govt IP address; Congress seeks PM Modi's reply
- No liberal approach, mediation or compromise in rape cases: Supreme Court
- Delhi court restrains release of controversial movie 'Mohalla Assi'